Introduction to MBMA Webinar – Presented by the ISoP SxP SIG

Introduction to MBMA

Matt Zierhut, Scientific Director, Statistics and Decision Science, Janssen, MBMA Sub-SIG Co-chair

Marion Bouillon-Pichault, Director, MBMA, Quantitative Clinical Pharmacology, BMS, MBMA Sub-SIG Co-chair

Tuesday January 26^th 12-1:30 pm EST

The Model-Based Meta-Analysis sub-Special Interest Group (MBMA sub-SIG) and the Statistics and Pharmacometrics Special Interest group (SxP SIG) within ISoP would like to invite you to the “Introduction to MBMA” Webinar!

Click her to register in advance for this webinar (open to nonmembers)

Abstract: As landscapes for the treatment of many diseases have grown increasingly competitive and costs to conduct clinical trials have soared, it is critical to understand the landscape of available treatments, as well as the probability that a specific compound could compete successfully in this market.

Model-based meta-analysis (MBMA) is a tool for integrating prior knowledge, both public and proprietary, and for using it to inform discovery and development decisions. As in traditional meta-analysis, MBMA allows one to more precisely quantify a treatment effect by incorporating data from multiple studies. Inclusion of model parameters further enables quantification and explanation of variability observed across trials by accounting for differences in effect modifiers, such as treatments, doses, time, population characteristics, etc. Thus, MBMA is a powerful tool for predicting new, potentially interesting clinical scenarios through clinical trial simulation. Additionally, applying the MBMA to perform simulations can improve strategic decision-making by projecting the likelihood of achieving differentiable efficacy and/or safety.

This webinar will enable you to understand what MBMA is and will present some examples showing the impact it can have in drug development and other critical business decisions.